Get the Stockscreener App
0.00
100.00%
-3.65
After Hours:
3.66
3.66
+
Revance Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
See More
Previous Close:
$3.65
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$381.02M
Revenue:
$234.04M
Net Income/Loss:
$-323.92M
P/E Ratio:
0.00
EPS:
-3.8
Net Cash Flow:
$-223.46M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$3.66
52-Week Range:
$0.00
$7.56
Revance Therapeutics Inc Stock (RVNC) Company Profile
Name
Revance Therapeutics Inc
Sector
Industry
Phone
(615) 724-7755
Address
1222 DEMONBREUN STREET, NASHVILLE, CA
Compare RVNC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
0.00 | 381.02M | 234.04M | -323.92M | -223.46M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | Mizuho | Buy → Neutral |
| Jan-09-24 | Downgrade | Goldman | Buy → Neutral |
| Aug-16-23 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-22-22 | Initiated | Goldman | Buy |
| Oct-25-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-15-20 | Reiterated | Needham | Buy |
| Aug-11-20 | Resumed | Mizuho | Buy |
| Mar-23-20 | Downgrade | Goldman | Buy → Neutral |
| Dec-02-19 | Initiated | Goldman | Buy |
| Oct-30-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Feb-15-19 | Initiated | Wells Fargo | Market Perform |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
| Nov-16-18 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-17-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Apr-20-18 | Reiterated | Mizuho | Buy |
| Mar-27-18 | Initiated | Needham | Buy |
| Mar-05-18 | Initiated | Goldman | Buy |
| Jan-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-06-17 | Initiated | Guggenheim | Buy |
| Dec-06-17 | Reiterated | Mizuho | Buy |
| Nov-27-17 | Initiated | Barclays | Overweight |
| Nov-17-17 | Initiated | Mizuho | Buy |
| Aug-22-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Revance Therapeutics Inc Stock (RVNC) Latest News
GLAZER CAPITAL, LLC Acquires Significant Stake in Revance Therap - GuruFocus.com
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of - GlobeNewswire
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Revance’s acquisition by Crown Laboratories completed - TipRanks
Revance Therapeutics Finalizes Merger with Crown Laboratories - TipRanks
Crown Labs completes acquisition of Revance Therapeutics - Investing.com
Major Aesthetics Deal: Crown Labs Acquires Revance as Shareholders Cash Out at Premium - StockTitan
Taking a Closer Look At Revance Therapeutics Inc (RVNC) Following Its Recent Trade - Knox Daily
Lawsuit Alert: Investors who lost money with shares of Revance - openPR
Revance Therapeutics sells to Crown Laboratories - The Business Journals
Revance Therapeutics Inc’s Shares Reel: -37.07% Quarterly Revenue Decline Amid 381.02M Market Cap - The InvestChronicle
Revance Therapeutics, Crown Laboratories Announce Expiration of Tender Offer -February 05, 2025 at 10:39 am EST - Marketscreener.com
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer - Marketscreener.com
Major Biotech Deal: Revance Shareholders Back Crown Labs Takeover with Massive 82% Support Rate - StockTitan
ForexTV | Small Business Resources - ForexTV.com
RVNC INVESTOR ALERT: Kirby McInerney LLP Notifies Revance Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit - yourbigsky.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesRVNC - PR Newswire
Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors - GlobeNewswire
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your RightsRVNC - PR Newswire
RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
2025-02-03 | Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC | NDAQ:RVNC | Press Release - Stockhouse Publishing
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class ActionRVNC - PR Newswire
2025-02-02 | Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC | NDAQ:RVNC | Press Release - Stockhouse Publishing
Mizuho maintains neutral on Revance, price target steady at $3.65 - MSN
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
Teoxane withdraws takeover offer for Revance Therapeutics - MSN
2025-01-31 | Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineRVNC | NDAQ:RVNC | Press Release - Stockhouse Publishing
Revance Therapeutics, Inc. Class Action Lawsuit Alert: - GlobeNewswire
Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline - Citizentribune
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) - GuruFocus.com
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC - Victoria Advocate
Revance Therapeutics set to go private with Crown Laboratories - The Business Journals
Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire
2025-01-30 | Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NDAQ:RVNC | Press Release - Stockhouse Publishing
Mizuho maintains Neutral on Revance, price target at $3.65 - Investing.com
Mizuho maintains Neutral on Revance, price target at $3.65 By Investing.com - Investing.com Canada
Mizuho maintains neutral on Revance, price target steady at $3.65 By Investing.com - Investing.com UK
Teoxane Ends Revance Pursuit After Revised Crown Deal - MarketWatch
2025-01-30 | Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky | NDAQ:RVNC | Press Release - Stockhouse Publishing
The Gross Law Firm Reminds Revance Therapeutics, Inc. Investors - GuruFocus.com
The Gross Law Firm Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025RVNC - PR Newswire
2025-01-29 | Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for InvestorsContact Levi & Korsinsky | NDAQ:RVNC | Press Release - Stockhouse Publishing
Dermata Unveils Game-Changing Skin Disease Treatment Progress: CEO Reveals What's Next - StockTitan
2025-01-29 | Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky | NDAQ:RVNC | Press Release - Stockhouse Publishing
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Consensus Target Price from Brokerages - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesRVNC - Longview News-Journal
2025-01-28 | Revance Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before March 4, 2025 to Discuss Your RightsRVNC | NDAQ:RVNC | Press Release - Stockhouse Publishing
Shareholders of Revance Therapeutics, Inc. Should Contact Levi & - GuruFocus.com
Revance Therapeutics Inc Stock (RVNC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):